ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because the usual routine of deadlines, meetings, phone calls, and what-not has just returned. You knew this would happen, though, yes? To cope, as always, we are quaffing cups of stimulation, especially given the bitter cold enveloping the Pharmalot campus this morning. Please feel free to join us. Meanwhile, here are the usual tidbits to get you started. Hope you have a productive day and, of course, do keep in touch…
Regeneron Pharmaceuticals received a subpoena last month from the US Attorney’s Office in Boston for documents concerning support of nonprofits that provide financial assistance to patients, according to a filing with the US Securities and Exchange Commission (see page 58). The subpoena mentioned the Eylea macular degeneration medicine, among others. The feds are also probing such programs run by other drug makers.